WuXi AppTec’s sales are becoming even more increasingly dependent on the US despite the service provider not yet fully shaking off concerns over its ties with the Chinese military.
READ MOREGSK’s recent deal to license out a rare liver disease drug just got sweeter.
READ MOREIn a rare move, the FDA last week posted photographs of dilapidated buildings as part of a warning letter for a Daman, India-based drug manufacturing facility.
READ MORENovartis is the latest drugmaker to invest in its Chinese footprint, with a pledge of more than 3.3 billion yuan ($480 million) to bolster two manufacturing and R&D sites.
READ MORE